AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Crispr TherapeuticsAllogene TherapeuticsHalozyme Therapeuticsbluebird bioAudentes Therapeutics
SymbolNASDAQ:CRSPNASDAQ:ALLONASDAQ:HALONASDAQ:BLUENASDAQ:BOLD
Price Information
Current Price$68.36$47.46$24.27$65.13$59.97
52 Week RangeBuyBuyBuyBuyHold
Beat the Market™ Rank
Overall Score1.21.32.21.50.9
Analysis Score2.42.33.44.41.1
Community Score2.52.32.63.02.6
Dividend Score0.00.00.00.00.0
Ownership Score1.02.03.00.01.0
Earnings & Valuation Score0.00.01.90.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$74.42$46.15$28.63$115.47$50.75
% Upside from Price Target8.87% upside-2.75% downside17.94% upside77.29% upside-15.37% downside
Trade Information
Market Cap$4.15 billion$6.04 billion$3.30 billion$3.58 billion$2.77 billion
Beta2.3421.742.392.18
Average Volume1,015,389935,2131,710,0101,247,1761,504,389
Sales & Book Value
Annual Revenue$289.59 millionN/A$195.99 million$44.67 millionN/A
Price / Sales14.40N/A16.8281.14N/A
Cashflow$1.37 per shareN/AN/AN/AN/A
Price / Cash49.79N/AN/AN/AN/A
Book Value$17.02 per share$5.16 per share$0.63 per share$23.22 per share($7.48) per share
Price / Book4.02N/A38.522.80N/A
Profitability
Net Income$66.86 million$-184,590,000.00$-72,240,000.00$-789,610,000.00$-128,820,000.00
EPS$1.17($1.83)($0.50)($14.31)($3.40)
Trailing P/E Ratio91.15N/AN/AN/AN/A
Forward P/E RatioN/AN/A15.56N/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins15.73%N/A-48.75%-1,531.04%N/A
Return on Equity (ROE)6.54%-33.05%-48.92%-60.05%N/A
Return on Assets (ROA)5.54%-29.27%-17.36%-46.17%-38.00%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.08%6.66%0.16%N/A
Current Ratio16.87%18.81%11.14%5.25%12.80%
Quick Ratio16.87%18.81%10.15%5.25%12.79%
Ownership Information
Institutional Ownership Percentage57.97%57.97%95.37%N/A96.33%
Insider Ownership Percentage17.10%36.50%2.60%3.00%5.30%
Miscellaneous
Employees1881222811,090207
Shares Outstanding61.02 million125.33 million135.82 million55.65 million46.27 million
Next Earnings Date8/3/2020 (Estimated)8/5/2020 (Estimated)8/4/2020 (Estimated)8/6/2020 (Estimated)N/A
OptionableOptionableNot OptionableOptionableOptionableOptionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.